SCHEMBL4869124

SCHEMBL4869124

O=C(CNS(=O)(=O)c1c(Cl)cccc1Cl)Nc1ccc(Cl)cc1Cc1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KCNJ5 P48544 1/20 0.42
KCNJ3 P48549 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
PTGES O14684 1/20 0.40
TP53 P04637 1/20 0.39
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRA1 P14867 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3256141 0.89 PTGES (0.47) GAALMNAALDH1A1MAPTMEN1
SCHEMBL3253246 0.89 MEP1B (0.48) GAALMNAALDH1A1MAPTHTT
SCHEMBL3249160 0.89 ALDH1A1 (0.53) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL3255473 0.86 ALDH1A1 (0.47) GAALMNAALDH1A1MAPTMEN1
SCHEMBL3247111 0.86 FLT1 (0.48) SMN1; SMN2LMNAALDH1A1MAPTMEN1
SCHEMBL3244433 0.85 PTGES (0.44) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL3251190 0.85 ALDH1A1 (0.46) GAALMNAALDH1A1MAPTMEN1
SCHEMBL3250641 0.84 MAPT (0.42) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL3249346 0.83 MAPT (0.41) GAALMNAALDH1A1MAPTMEN1
SCHEMBL4868971 0.83 MAPT (0.41) LMNAALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 GAA 746/4885SMN1; SMN2 22/4885LMNA 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.